What You Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Targeted Exposure Analysis

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about the connection to gastroparesis. Building on decades of medical research into drug safety and gastrointestinal health, this page provides an objective overview of what science currently says about Ozempic and delayed gastric emptying.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may result in malnutrition, dehydration, and electrolyte imbalances. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology includes slowing gastric emptying, which contributes to glycemic control but also underlies many gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which slows gastric motility. This pharmacodynamic effect can become pathological in susceptible individuals, leading to clinically significant delayed gastric emptying. While the prescribing information does not explicitly list gastroparesis as a warning, the high rates of nausea, vomiting, and abdominal pain—symptoms that overlap with gastroparesis—suggest a potential link. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The label includes a warning for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically address gastroparesis. This gap may be relevant for patients who developed the condition after using Ozempic and argue that the manufacturer failed to provide adequate risk information.

Statute of Limitations for Ozempic Claims in Massachusetts

For affected patients in Massachusetts, settlement-related considerations depend on the statute of limitations for product liability claims. In Massachusetts, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. For claims involving harm from a prescription drug, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the drug caused the injury. Given that gastroparesis symptoms may develop gradually and be misattributed to other causes, the timeline between exposure and documented harm is critical. Patients who used Ozempic and later received a gastroparesis diagnosis should document the date of first use, duration of use, onset of symptoms, and date of formal diagnosis. This timeline will help determine whether the claim falls within the statutory period. Settlement considerations also include the strength of evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the adequacy of the manufacturer's warnings. While the clinical trial data show elevated rates of gastrointestinal adverse reactions, direct evidence of gastroparesis as a distinct adverse event is limited. Patients with documented gastroparesis confirmed by gastric emptying scintigraphy and a clear temporal relationship to Ozempic use may have stronger claims. Legal counsel should review the specific facts of each case, including any communications from the manufacturer about the risk. In summary, Massachusetts patients who developed gastroparesis after using Ozempic should be aware of the three-year statute of limitations, which may be triggered by the date of diagnosis or discovery of the link to the drug. The high incidence of gastrointestinal adverse reactions in clinical trials supports a plausible mechanistic connection, but the absence of a specific gastroparesis warning may be a point of contention in settlement negotiations. Affected individuals are advised to consult with an attorney experienced in pharmaceutical litigation to assess their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. For prescription drug claims, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that the drug caused the injury.

What evidence links Ozempic to gastroparesis?

Clinical trial data show elevated rates of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain in Ozempic users, which overlap with gastroparesis symptoms. Mechanistically, Ozempic slows gastric emptying via GLP-1 receptor activation, which can become pathological. However, the prescribing information does not specifically list gastroparesis as a warning.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.